Paper Details

  1. Home
  2. Paper Details

A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.

Author: AllhoffErnst P, FilleurStephanie, KalinskiThomas, KlatteTobias, NeliusThomas, RöpkeAlbrecht, YapRon

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Docetaxel, a chemotherapy drug, is increasingly used for men with hormone-refractory prostate cancer (HRPC). The combination of docetaxel with different doses of estramustine is being investigated to improve response rates and reduce side effects.
Paper Details　
Original Abstract of the Article :
To test the combination of docetaxel with two different doses of estramustine in patients with hormone-refractory prostate cancer (HRPC), to improve response rates and to lower side-effects, as docetaxel-based chemotherapy is an increasing option for men with advanced HRPC, and alone or combined wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1464-410X.2006.06324.x

データ提供：米国国立医学図書館（NLM）

Docetaxel and Estramustine for Hormone-Refractory Prostate Cancer

The fight against hormone-refractory prostate cancer (HRPC) is a challenging and often arduous journey, much like traversing a scorching desert landscape. This research delves into the effectiveness of combining docetaxel with two different doses of estramustine as a potential therapeutic strategy for patients with HRPC.

The study aimed to determine if combining docetaxel with different doses of estramustine could improve response rates and reduce side effects, offering a more effective and tolerable treatment for patients with HRPC. This approach aimed to optimize the therapeutic benefits while minimizing the burden of treatment.

The findings suggest that combining docetaxel with either low or high doses of estramustine may be a viable option for treating patients with HRPC. The study indicates a potential for improving response rates and managing side effects. Further research is needed to refine the optimal dosing strategy for this combination therapy.

Navigating Treatment Options for HRPC

This study highlights the ongoing efforts to develop more effective and tolerable treatments for HRPC. The combination of docetaxel and estramustine offers a potential avenue for improving response rates and quality of life for patients battling this disease.

Hope for Patients with HRPC

The research offers a glimmer of hope for patients with HRPC, suggesting that a combination of docetaxel and estramustine may be an effective and tolerable therapeutic option. Further research is needed to optimize the dosing strategy and further investigate the long-term benefits of this approach.

Dr.Camel's Conclusion

In the fight against HRPC, scientists are constantly searching for new oases of hope. This research explores the potential of combining docetaxel and estramustine, offering a promising path toward more effective and tolerable treatment for patients facing this challenging disease.

Date :
  1. Date Completed 2006-09-21
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

16925757

DOI: Digital Object Identifier

10.1111/j.1464-410X.2006.06324.x

Related Literature

Article Analysis
・Side Effects of estramustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.